Novartis AG (NVS)
| Market Cap | 188.59B |
| Revenue (ttm) | 48.68B |
| Net Income (ttm) | 11.73B |
| Shares Out | 2.31B |
| EPS (ttm) | 3.52 |
| PE Ratio | 23.87 |
| Forward PE | 13.83 |
| Dividend | $3.40 |
| Dividend Yield | 4.05% |
| Trading Day | March 5 |
| Last Price | $84.01 |
| Previous Close | $83.50 |
| Change ($) | 0.51 |
| Change (%) | 0.61% |
| Day's Open | 83.36 |
| Day's Range | 82.29 - 84.24 |
| Day's Volume | 2,019,527 |
| 52-Week Range | 66.51 - 94.72 |
Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.
Basel, March 5, 2021 — Novartis announced today that Shannon Thyme Klinger, Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotech...
Swiss Pharma giant Novartis AG (NYSE: NVS) has agreed to help CureVac BV (NASDAQ: CVAC) produce its experimental COVID-19 vaccine, known as CVnCoV. Novartis plans to manufacture the mRNA molec...
Basel, March 2, 2021 — Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting (AGM). In accordance wit...
Homology Medicines Inc (NASDAQ: FIXX) has regained worldwide exclusive rights from Novartis AG (NYSE: NVS) to research, develop, manufacture, and commercialize its proprietary nuclease-free ge...
making Novartis an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of NVS entered into oversold territory, changing hands as low as $86.472 pe...
When a company's return on equity (ROE) ratio outperforms most of its peers, it indicates the company has been very efficient in generating earnings.
EAST HANOVER, N.J., Feb. 16, 2021 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitr...
Basel, February 11, 2021 – Sandoz, a Novartis division, has signed an agreement to acquire GSK's cephalosporin antibiotics business, reinforcing its leading global position in antibiotics.
Novartis' (NVS) asciminib gets Breakthrough Therapy tag by the FDA for the treatment of adult patients with Ph+ CML in chronic phase, previously treated with two or more tyrosine kinase inhibi...
The unusual biotech could be a bitter pill for short sellers to swallow.
Week In Review: Matridx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices
The digital press release with multimedia content can be accessed here:
Novartis CEO Says Firm Can Help Other Companies Make Vaccines
Jan.28 -- Novartis AG CEO Vas Narasimhan tells Bloomberg Television that the drugmaker is in talks with "a range of different players" to help produce other companies' Covid-19 vaccines or tre...
Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.
Novartis AG (NVS) CEO Vas Narasimhan on Q4 2020 Results - Earnings Call Transcript
Novartis CEO discusses developing a new Covid-19 treatment
Vas Narasimhan, Novartis CEO, joins 'Closing Bell' to talk about developing a new Covid-19 treatment that uses something called DARPin (Designed Ankyrin Repeat Proteins) "We hope by the summer...
Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S...
Novartis stock toppled Tuesday after the drug company said it expects the coronavirus pandemic to weigh on prescription sales until mid-2021. Shares remained above a buy point, however.
Shares of Novartis (NYSE:NVS) decreased 3.8% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 1.52% over the past year to $1.34, whic...
Novartis Chief Executive Vas Narasimhan on Tuesday renewed his commitment to his Sandoz generic unit where sales growth in 2020 stagnated due to reduced hospital stays during the COVID-19 pand...
Novartis CEO: Hopeful to Accelerate Growth in Second Half
Jan.26 -- Vas Narasimhan, chief executive officer at Novartis AG, discusses his outlook for the second half of the year, the vaccine rollout and the long-term impact of Covid-19. He speaks on ...
Novartis (NYSE:NVS) announces its next round of earnings this Tuesday, January 26. Here is Benzinga's look at Novartis's Q4 earnings report.
BeiGene out-licensed ex-China rights for tislelizumab, its China-approved anti-PD-1 antibody, to Novartis in a $2.2 billion agreement. Inmagene in-licensed global rights to four novel pre-clin...
Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Ho...
Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.
Those are some solid endorsements.
Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.
Novartis CEO on ESG: Pandemic has been a reset for pharma's reputation
Novartis CEO Dr. Vas Narasimhan joins CNBC's "Halftime Report" team and Meg Tirrell to discuss the pharma industry amid the pandemic.
Beigene stock jumped Tuesday on a cancer drug development deal with Novartis worth up to $2.2 billion, as Vir Biotechnology also announced a hepatitis B tie-up with Gilead Sciences. The post B...
Novartis AG (NVS) CEO Vas Narasimham Presents at 39th Annual J.P. Morgan Virtual Healthcare Conference (Transcript)
Basel, January 11, 2021 — Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential fo...
Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.
Novartis has underperformed other healthcare stocks so far. Value remains within normal P/E range.
3 Large Drugmakers Set to Rule the Sector in 2021
Getting in on the extensive merger and acquisition game of large pharmaceutical companies is the ultimate endgame for Exelixis, a biotech that already boasts an established cancer-focused prod...
Novartis (NVS) gets CRL from the FDA for its cholesterol drug, inclisiran, due to unresolved facility inspection-related conditions.
The FDA's inability to inspect an overseas manufacturing facility is holding up an application for inclisiran.
Basel, December 18, 2020 — The U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for inclisiran, a potential treatmen...
Novartis (NVS) to buy neuroscience company, Cadent, for up to $770 million.
Novartis said on Thursday it had entered into an agreement to acquire U.S.-based neuroscience company Cadent for up to $770 million, gaining full rights to Cadent's neuroscience portfolio.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cadent Therapeutics, a privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, ...
Novartis (NVS) gets positive review from the FDA Advisory Committee to support the use of Entresto in the treatment of patients with heart failure with preserved ejection fraction.
Novartis' bid to pump up sales of its Entresto heart failure medicine beyond $5 billion annually got a boost when a U.S. Food and Drug advisory panel recommended it be used to treat a differen...
Basel, December 16, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 12 to 1 that the data present...
Novartis' (NVS) late-stage study on ruxolitinib in COVID-19 patients did not meet its primary endpoint.
Basel, December 15, 2020 — Novartis today announced positive findings from the first interpretable results of the Phase III KESTREL study, assessing the efficacy and safety of Beovu® (broluciz...
Basel, December 14, 2020 — Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patient...
Basel, December 9 , 20 20 — Novartis today announced new Kisqali® (ribociclib) data demonstrating consistent efficacy benefit with Kisqali plus endocrine therapy across the main intrinsic subt...
According to the All-in-One Screener, a Premium feature of GuruFocus, four German and Swiss companies with at least four gurus owning shares are Novartis AG (XSWX:NOVN)(NYSE:NVS), Nestle SA (X...
About NVS
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to... [Read more...]
| Industry Drug Manufacturers-General | IPO Date Nov 18, 1991 |
| CEO Joseph Jimenez | Employees 105,794 |
| Stock Exchange NYSE | Ticker Symbol NVS |
Financial Performance
In 2019, Novartis's revenue was $48.68 billion, an increase of 5.59% compared to the previous year's $46.10 billion. Earnings were $11.73 billion, a decrease of -6.97%.
Analyst Forecasts
According to 5 analysts, the average rating for Novartis stock is "Strong Buy." The 12-month stock price forecast is 104.67, which is an increase of 24.59% from the latest price.